Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Tracheal Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Breast Cancer 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Combined Modality Therapy × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡